Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunology
Open single-cell discovery grant for oncology and immunology up to 100K Euro aimed at addressing unmet clinical needs.
Immunological diseases and Cancer are complex disorders and pose an enormous clinical burden due to diagnosis, stratification, and treatment challenges. Single-cell technologies are powerful in analysing the cellular landscape within complex diseases and are increasingly popular as a tool in identifying rare cells underlying the etiology of disease onset and progression in these areas. We are opening a single-cell discovery grant for oncology and immunology.
Scailyte is a recognized leader in combining single-cell analysis with artificial intelligence (AI) based data analytics. Our best-in-class algorithm associates patterns in single-cell data with disease status and further integrates multiple clinical parameters for a sensitive and impactful discovery.
We offer a co-finance partnership sharing 50% of costs (up to 100K Euro) for single-cell data acquisition including scRNA sequencing and CyTOF analysis, and subsequent artificial intelligence (AI)-based high-end bioinformatics services for translational oncology and immunology projects. The expected outcome of these grants should be addressing unmet medical needs and targets the discovery of clinically relevant biosignatures from single-cell data for diagnostic and prognostic pharmaceutical use. A maximum of three projects will be selected for this award through a formal selection process and notified within one month of the deadline.
Application:
Link to the brief application form: Click Here
Deadline: 30th September 2021
Recent News
Scailyte Extends Series A to USD 8 Million
We are thrilled to announce the extension of our Series A funding, bringing the total raised amount ...
Recent News
ScaiDigest Volume 6: Variational autoencoders (VAEs) in biology
Welcome to the 6th edition of ScaiDigest, where we explore cutting-edge research in single-cell anal...
Recent News
Pitch-nic Expo
We're excited to share that our Senior Vice President of Corporate & Technology Development, Corinne...
Recent News
Targets & Cell Types in Immuno-Oncology Europe 2023
Scailyte is part of Targets & Cell Types in Immuno-Oncology Europe 2023 event on November 14-15 in B...
Recent News
Unravelling the AI Executive Order: A Discussion with Our CEO and Head of Regulatory Affairs
We invite you to watch this enlightening discussion to gain valuable insights into the evolving AI l...
Recent News
NextGen Omics 2023
Scailyte is gearing up for NextGen Omics 2023, one of the most scientifically engaging events in Lon...
Recent News
Recent News
ScaiDigest Volume 5: Unlocking the Secrets of AML
Read Diana's insightful post and stay at the forefront of scientific advancements in the field!
Recent News
Scailyte Extends Series A to USD 8 Million
We are thrilled to announce the extension of our Series A funding, bringing the total raised amount ...
ScaiDigest Volume 6: Variational autoencoders (VAEs) in biology
Welcome to the 6th edition of ScaiDigest, where we explore cutting-edge research in single-cell anal...
Recent News
Pitch-nic Expo
We're excited to share that our Senior Vice President of Corporate & Technology Development, Corinne...
Targets & Cell Types in Immuno-Oncology Europe 2023
Scailyte is part of Targets & Cell Types in Immuno-Oncology Europe 2023 event on November 14-15 in B...
Recent News
Unravelling the AI Executive Order: A Discussion with Our CEO and Head of Regulatory Affairs
We invite you to watch this enlightening discussion to gain valuable insights into the evolving AI l...
NextGen Omics 2023
Scailyte is gearing up for NextGen Omics 2023, one of the most scientifically engaging events in Lon...
Recent News
SITC 2023
Diana Stoycheva and Julian Spagnuolo will be sharing Scailyte’s science at a poster #201, and will...
ScaiDigest Volume 5: Unlocking the Secrets of AML
Read Diana's insightful post and stay at the forefront of scientific advancements in the field!